An adolescent with HTLV-I-associated adult T cell leukemia treated with interferon-alfa and zidovudine.

Alberto Broniscer(St Nicholas Hospital), Parkash S. Gill(University of Southern California), R. C. Ribeiro(St. Jude Children's Research Hospital), David R. Head(University of Southern California), Frederick G. Behm(St. Jude Children's Research Hospital), Belinda N. Mandrell(St. Jude Children's Research Hospital), R V Srinivas(St. Jude Children's Research Hospital), S Raimondi(University of Tennessee Health Science Center)
PubMed
July 1, 1996
Cited by 10

Related Papers

Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study
|Blood|2000|1.6k
Age and acute myeloid leukemia
|Blood|2006|1.4k
Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia
|The Lancet Oncology|2009|1k
Cancer-Related Fatigue, Version 2.2015
|Journal of the National Comprehensive Cancer Network|2015|951
Acute Myeloid Leukemia in the Elderly: Assessment of Multidrug Resistance (MDR1) and Cytogenetics Distinguishes Biologic Subgroups With Remarkably Distinct Responses to Standard Chemotherapy. A Southwest Oncology Group Study
|Blood|1997|869